Having trouble accessing articles? Reset your cache.

King, Pfizer deal

Pfizer will acquire King in a tender offer of $14.25 per share, or $3.6 billion in cash. The price

Read the full 198 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE